Chairman: Prof. E.N. Nikolaev (Institute of Energy Problems of Chemical Physics RAS, Moscow, Russia), Chairlady: Prof. I.M. Larina (SSC RF Institute for Biomedical Problems, RAMS, Moscow, Russia), Chairlady: E. Schwartz (Ariadne Diagnostics LLC, USA).
This session will be focused on biomarkers and specifically omics-based strategy to identify biomarkers and pharmacological targets in different diseases. The increasing amounts of data, generated by experimental methods, challenges researchers to extract biologically applicable information. New computational methods for data analysis improve the quality of prospective biomarkers, presenting approaches for more effective verification and validation of biomarkers. Systems biology and pathway analysis may be the key that researchers need to rapidly discover, qualify and select appropriate biomarkers before large investment spent for their development. In addition, the complex interactions of targeted biomarkers can be mapped across multiple cellular processes and diseases providing a window into potential risks and benefits, before and during clinical trials, allowing companies to maximize their resources towards the development of targeted and individualized therapies. Several software packages available now provide for researchers the flexibility to import their experimental profiling data, find key regulators that could also be biomarkers from this data, and store this information in searchable databases. This innovative technology is particularly appropriate for the identification of new biomarkers for different diseases in the field of personalized medicine. The technology works to select biological pathways that are closely related to a clinical outcome of interest, by using proteomics or other “omics” data; and leverages its comprehensive database of pathway-related information containing relationships between proteins, cell processes, small molecules, and more. Thus, computational approaches for precision medicine together with the emergence of new high-throughput technologies for biomarker discovery are enabling comprehensive profiling of new biological pathways and molecular targets that can be more specific indicators of many devastated diseases including cancer and neurodegenerative disease.
Section topics include, but are not limited to:
- The role of proteomics in clinical pharmacology
- Biomarkers: bioinformatics/mathematical point of view
- Biomarkers in translational medicine
- Cancer pharmacology
- Proteomics in neuroscience
- Computational approaches to developing surrogate biomarkers for clinical trials